Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Johnson & Johnson-AbbVie Partnered Lymphoma Drug Slows Disease Progression, Data Shows

  • Johnson & Johnson (NYSE:JNJ) and AbbVie Inc (NYSE:ABBV) announced primary results from the Phase 3 SHINE study of Imbruvica (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance in older patients with newly diagnosed mantle cell lymphoma (MCL).
  • The combination regime significantly reduced the risk of disease progression or death by 25% compared to placebo plus BR and rituximab maintenance.
  • Median progression-free survival (PFS) was 80.6 months with ibrutinib combined with bendamustine-rituximab and rituximab maintenance.
  • That compared with 52.9 months for the chemotherapy regimen in the 523-patient trial.
  • MCL is a rare type of lymphoma with an incidence of around 1 case per 200,000 people a year.
  • The complete response rate was 65.5% in the ibrutinib group and 57.6% in the placebo.
  • There was no difference in overall survival (OS) between treatment groups. The patients in the study continue to be followed for longer-term OS.
  • Price Action: JNJ shares are up 0.65% at $177.57, and ABBV shares are down 0.36% at $146.64 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.